ipilimumab,nivolumab
bms
[]
update for checkmate 649 for 1st line advanced gastric cancer for nivolunab with chemo validated for 3-yr follow up #ascogi23 #ascogi #cancer #cancerresearch #clinicaltrials #immunotherapy 
Co-Director/Co-Leader GI Oncology Research; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee; and Director for Strategic Relations